Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 2058 • ACR Convergence 2022
Evidence on the Construct Validity of the Perceived Deficits Questionnaire Among Adult Patients with Systemic Lupus Erythematosus
Stefan Perera¹, Jiandong Su², Kathleen Bingham³, Mahta Kakvan¹, Maria Carmela Tartaglia⁴, Leslet Ruttan⁵, Joan Wither¹, May Choi⁶, Simone Appenzeller⁷, Dorcas Beaton⁸, Dennisse Bonilla², Patricia Katz⁹, Robin Green⁵, Michelle Barraclough¹⁰ and Zahi Touma², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, University of Toronto, Toronto, ON, Canada, ²Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ³Centre for Mental Health, University Health Network; Department of Psychiatry, University of Toronto, Toronto, ON, Canada, ⁴University of Toronto Krembil Neurosciences Centre, Toronto, ON, Canada, ⁵University Health Network-Toronto Rehabilitation Institute, Toronto, ON, Canada, ⁶Brigham and Women's Hospital | University of Calgary, Calgary, AB, Canada, ⁷Unicamp, Campinas, São Paulo, Brazil, ⁸Institute for Work & Health, Toronto, ON, Canada, ⁹UCSF, San Rafael, CA, ¹⁰Schroeder Arthritis Institute, Krembil Research Institute, University Health Network, Centre for Epidemiology Versus Arthritis, Division of Musculoskeletal and Dermatological Sciences, School of Biological Sciences, Faculty of Biology, Medicine and Health, The University of Manchester, NIHR Manchester Biomedical Research Centre, Manchester University NHS Foundation Trust, Manchester Academic Health Science Centre, Toronto, ON, Canada
Background/Purpose: Cognitive impairment (CI) is prevalent in SLE and negatively impacts social and occupational engagement. There is a need for a patient-reported outcome measure (PROM)…
Abstract Number: 2076 • ACR Convergence 2022
Unfavorable Outcomes Associated with Current Standard of Care in the Management of Patients with Systemic Lupus Erythematosus
Zahi Touma¹, Sheena Kayaniyil², Anna Parackal², Dennisse Bonilla¹, Jiandong Su¹, Christina Qian³, Sally Miller³, Shelagh Szabo³ and Shelly Chandran², ¹Schroeder Arthritis Institute, Krembil Research Institute, University Health Network and University of Toronto, Toronto, ON, Canada, ²AstraZeneca, Mississauga, ON, Canada, ³Broadstreet Health Economics & Outcomes Research, Vancouver, BC, Canada
Background/Purpose: The effectiveness of current standard of care treatment including corticosteroids (CS) in Systemic Lupus Erythematosus (SLE) is limited and has potential side-effects. Given the…
Abstract Number: 2096 • ACR Convergence 2022
Role of Cell-Bound Complement Fragments as Biomarkers to Determine Disease Activity in Patients with Systemic Lupus Erythematosus
Marcela Muñoz Urbano¹, Diana C. Quintero-González¹, Mauricio Rojas², Joaquín Rodelo¹, Alba Luz León Álvarez¹, Luis Gonzalez¹ and Gloria Vásquez³, ¹Universidad de Antioquia, Medellín, Colombia, ²Grupo de Inmunología Celular e Inmunogenética, GICIG, and Unidad de citometría de flujo, Sede de Investigación Universitaria, Universidad de Antioquia, Medellín, Colombia, ³Grupo de Inmunología Celular e Inmunogenética, GICIG and Grupo de Reumatología, Universidad de Antioquía, Medellín, Colombia
Background/Purpose: The prompt identification of patients with systemic lupus erythematosus (SLE) at risk of or in flare strongly influences the prognosis of the disease. Cell-bound…
Abstract Number: 2202 • ACR Convergence 2022
Association of Visit-based Retention and Receipt of Serologic Testing with Acute Care Use Among Young Adults with Lupus: A Medicare Cohort Study
Maria Schletzbaum¹, Brad C. Astor², W. Ryan Powell³, Shivani Garg⁴, Andrea Gilmore-Bykovskyi⁵, Joseph A. Kramer⁶, Amy J. Kind⁷ and Christie Bartels⁸, ¹University of Wisconsin School of Medicine and Public Health, Department of Population Health Sciences, Middleton, WI, ²University of Wisconsin School of Medicine and Public Health, Department of Medicine, Nephrology Division and Department of Population Sciences, Madison, WI, ³University of Wisconsin School of Medicine and Public Health, Center for Health Disparities Research, Thousand Oaks, CA, ⁴University of Madison, School of Medicine and Public Health, Madison, WI, ⁵University of Wisconsin School of Medicine and Public Health, Department of Emergency Medicine; and the Center for Health Disparities Research, Madison, WI, ⁶University of Wisconsin School of Medicine and Public Health, Department of Medicine & Center for Health Disparities Research,, Madison, WI, ⁷University of Wisconsin School of Medicine and Public Health, Department of Medicine, Geriatrics Division & Center for Health Disparities Research, Madison, WI, ⁸University of Wisconsin School of Medicine and Public Health, Madison, WI
Background/Purpose: While high quality lupus care is associated with less damage, the impact of care use patterns and care quality on lupus outcomes remains unclear,…
Abstract Number: 0106 • ACR Convergence 2022
A Systematic Review of Racial and Ethnic Disparities in Disease Related Outcomes Among Patients with SLE
Teresa Semalulu¹, Keerthana Pasumarthi¹, Kevin Zhao¹, Rauda AlDhaheri¹, Nadine Akbar², KAREN BEATTIE¹ and KONSTANTINOS TSELIOS³, ¹McMaster University, Hamilton, ON, Canada, ²Humber River Hospital and University of Toronto, Toronto, ON, Canada, ³McMaster University, Population Health Research Institute, Hamilton, ON, Canada
Background/Purpose: Racialized patients and ethnic minorities have worse outcomes in SLE. This is likely related to a complex interplay between genetic and non-genetic factors. Numerous…
Abstract Number: 0323 • ACR Convergence 2022
Identifying Distinct Phenotypes of Patients with Juvenile Systemic Lupus Erythematosus: Results from a Cluster Analysis by the Egyptian College of Rheumatology (ECR) Study Group
Nevin Hammam¹, Mohamed Bakrey Mahmoud², Aly Bakhiet³, Rasha El Owaidy⁴, Hend Abdel Nabi⁵, Ahmed M Elsaman⁶, Iman Khalifa⁷, Abeer M NourEl-Din⁸, Rawhya R ElShereef⁹, Eman Hassan¹⁰, Faten Ismail⁹, Iman I El-Gazzar¹¹, Abdelhafeez Moshrif¹², Noha M Khalil¹³, Marwa A Amer¹⁴, Hanan M Fathy¹⁵, Nancy Abdel Salam¹⁵, Samar Tharwat¹⁶, Mervat I Abd Elazeem¹⁷, Hanan M Fathi¹⁸ and Tamer A Gheita¹¹, ¹Rheumatology Department, Faculty of Medicine, Assiut University, Assiut, Egypt, PASADENA, CA, ²Higher Institute for Computer Science and Information Systems, 6th of October City, Cairo, Egypt, ³Higher Institute for Computer Science and Information Systems, 6th of October City, Assiut, Egypt, ⁴Pediatric Allergy, Immunology and Rheumatology Unit, Children's Hospital, Ain Shams University, Cairo, Egypt, ⁵Pediatrics Department, Rheumatology and Nephrology Unit, Tanta University, Gharbia, Egypt, ⁶Rheumatology Department, Faculty of Medicine, Sohag University, Sohag, Egypt, ⁷Pediatrics Department, Rheumatology and Nephrology Unit, Helwan University, Cairo, Egypt, ⁸Pediatrics Department, National Research Centre (NRC), Cairo, Egypt, ⁹Rheumatology Department, Faculty of Medicine, Minia University, Minia, Egypt, ¹⁰Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹¹Rheumatology Department, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹²Rheumatology Department, Faculty of Medicine, Al-Azhar University, Assiut, Egypt, ¹³Internal Medicine Department, Rheumatology Unit, Faculty of Medicine, Cairo University, Cairo, Egypt, ¹⁴Rheumatology Department, Faculty of Medicine, Alexandria University, Alexandria, Egypt, ¹⁵Pediatrics Department, Rheumatology and Nephrology Unit, Alexandria University, Alexandria, Egypt, ¹⁶Internal Medicine, Rheumatology Unit, Mansoura University, Dakahlia, Egypt, Dakahlia, Egypt, ¹⁷Rheumatology Department, Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, ¹⁸Rheumatology Department, Faculty of Medicine, Fayoum University, Fayoum, Egypt
Background/Purpose: Juvenile systemic lupus erythematosus (J-SLE) is a complex autoimmune disease characterized by a great heterogeneity in organs involvement. A better understanding of the organ…
Abstract Number: 0340 • ACR Convergence 2022
Birth Order Is a Risk Factor for Systemic Lupus Erythematosus
Nicole Shammas¹, Priya Ramani², Christopher Aston³, Ana Quintero-Del-Rio⁴, Judith James⁵, John Harley⁶, Isaac Harley⁷ and Hal Scofield⁵, ¹University of Colorado School of Medicine, Aurora, CO, ²Tampa Rheumatology, Tampa, FL, ³University of Oklahoma Health Sciences Center, Oklahoma City, OK, ⁴OU Children's Hospital, Oklahoma City, OK, ⁵Oklahoma Medical Research Foundation, Oklahoma City, OK, ⁶US Department of Veterans Affairs Medical Center, Cincinnati, OH, ⁷University of Colorado Anschutz Medical Campus, Aurora, CO
Background/Purpose: Birth order effects have been described in several immune and non-immune disease states. While some studies have found an increased risk of developing autoimmune…
Abstract Number: 0361 • ACR Convergence 2022
Gene Expression Pathways Modulated by Anifrolumab in Systemic Lupus Erythematosus
Tina Baker¹, Sharifian Hoda², Paul Newcombe¹, Mark Lazarus¹, Madhu Ramaswamy³, Nicola Ferrari¹, Daniel Muthas², Hussein Al-Mossawi¹, Raj Tummala³, Eric F. Morand⁴, Richard A. Furie⁵, Edward Vital⁶ and Philip Brohawn³, ¹AstraZeneca, Cambridge, United Kingdom, ²AstraZeneca, Gothenburg, Sweden, ³AstraZeneca, Gaithersburg, MD, ⁴Monash University, Melbourne, Australia, ⁵Northwell Health, Great Neck, NY, ⁶University of Leeds, Leeds, England, United Kingdom
Background/Purpose: Anifrolumab is a monoclonal antibody to IFN-α receptor 1 that inhibits type I IFN signaling. In the phase 3 TULIP-1 and TULIP-2 trials, anifrolumab…
Abstract Number: 0572 • ACR Convergence 2022
ACR Workgroup to Develop Recommendations for PRO Use in Clinical Care for SLE
Patricia Katz¹, Claire Barber², Ali Duarte-Garcia³, Shivani Garg⁴, Wambui Machua⁵, Yesenia Santiago-Casas⁶, Wendy Rodgers⁷, Lisa Suter⁸, Jennifer Ude⁹, Tracy Johansson⁹, Christie Bartels¹⁰ and Jinoos Yazdany¹¹, ¹UCSF, San Rafael, CA, ²University of Calgary, Calgary, AB, Canada, ³Mayo Clinic, Rochester, MN, ⁴University of Madison, School of Medicine and Public Health, Madison, WI, ⁵Piedmont Physicians, Rheumatology, Atlanta, GA, ⁶Integral Rheumatology and Immunology Specialists, Plantation, FL, ⁷Lupus Foundation of America, Torrance, CA, ⁸Yale School of Medicine, New Haven, CT, ⁹American College of Rheumatology, Atlanta, GA, ¹⁰University of Wisconsin School of Medicine and Public Health, Madison, WI, ¹¹UCSF, San Francisco, CA
Background/Purpose: Patient-reported outcome (PRO) measures are not consistently used in clinical settings for patients with systemic lupus erythematosus (SLE). As part of a Centers for…
Abstract Number: 0644 • ACR Convergence 2022
Long-lived Plasma Cells in the Lupus Bone Marrow Are Imprinted by Interferon
Jennifer Barnas¹, Diana Alzamareh², Neha Nandedkar-Kulkarni², Jennifer Albrecht², Nida Meednu², Cameron Baker², Andrew McDavid¹ and Jennifer Anolik², ¹University of Rochester, Rochester, NY, ²University of Rochester Medical Center, Rochester, NY
Background/Purpose: Systemic lupus erythematous (SLE) is a complex autoimmune disorder with heterogeneous disease presentation and a multi-pronged pathogenesis. Although autoreactive plasma cells (PC) play a…
Abstract Number: 0665 • ACR Convergence 2022
Screening for Neurocognitive Demands in Childhood-onset Systemic Lupus Erythematosus Patients Using Pediatric Automated Neuropsychological Assessment Metrics and Association with Magnetic Resonance Imaging
Jaqueline De Amorim¹, Simone Kishimoto¹, Danilo Pereira¹, Letícia Rittner¹ and Simone Appenzeller², ¹University of Campinas, Campinas, São Paulo, Brazil, ²Unicamp, Campinas, São Paulo, Brazil
Background/Purpose: Neuropsychiatric manifestations are frequently seen in patients with childhood-onset erythematosus (cSLE) and may include neurocognitive dysfunction. These symptoms are difficult to diagnose and classify…
Abstract Number: 0939 • ACR Convergence 2022
Pilot Study: A Novel Method for Cervical Health Monitoring in African American Women with Systemic Lupus Erythematosus (SLE) Using a Self- Sampling Brush to Assess Cervical HPV Infection and Cervical Cytology
J. Patricia Dhar¹, Heather Walline², Lamia Fathallah³, Susanna Szpunar⁴, Louis Saravolatz⁵, Gil Mor⁶ and Thomas Carey⁷, ¹Ascension St. John Hospital and Wayne State University School of Medicine, Bloomfield Hills, MI, ²University of Michigan, Ann Arbor, MI, ³Ascension St.John Hospital, Detroit, MI, ⁴Ascension St. John Hospital, Grosse Pointe Woods, MI, ⁵Ascension St John Hospital and Medical Center, Wayne State University School of Medicine (affiliate), Grosse Pointe Woods, MI, ⁶Wayne State University and C.S. Mott Center for Human Growth and Development., Detroit, MI, ⁷University of Michigan School of Medicine, Ann Arbor, MI
Background/Purpose: A health disparity exists for AA women with SLE who have increased morbidity & mortality from both cervical cancer & SLE. Current cervical cancer…
Abstract Number: 0974 • ACR Convergence 2022
Rapid Efficacy of Anifrolumab Across Multiple Subtypes of Recalcitrant Cutaneous Lupus Erythematosus Parallels Discrete Changes in Transcriptomic and Cellular Biomarkers
Lucy Marie Carter¹, Zoe Wigston¹, Jack Arnold¹ and Philip Laws², ¹University of Leeds, Leeds, United Kingdom, ²Leeds Teaching Hospitals NHS Trust, Leeds, United Kingdom
Background/Purpose: Cutaneous lupus eyrthematosus (CLE) is frequently refractory to immunosuppressive therapies including B-cell depletion, but response varies by morphology with the chronic discoid (DLE) subtype…
Abstract Number: 0991 • ACR Convergence 2022
Prior Use of Autoimmune Disease Treatments Among Patients with Systemic Lupus Erythematosus, Rheumatoid Arthritis, or Myositis Hospitalized with COVID-19
Cassandra Calabrese¹, Gelareh Atefi², Kristin Evans³, Meghan Moynihan³, Liisa Palmer³ and Sandra Sze-jung Wu⁴, ¹Cleveland Clinic Foundation, Cleveland Heights, OH, ²AstraZeneca, Wilmington, DE, ³Merative, Cambridge, MA, ⁴AstraZeneca, Hockessin, DE
Background/Purpose: To compare use of autoimmune disease treatments between patients with and without severe COVID-19 (COVID) in cohorts of patients with systemic lupus erythematosus (SLE),…
Abstract Number: 1115 • ACR Convergence 2022
Medication Co-pay Modifies Treatment Adherence in Patients with Systemic Lupus Erythematosus
Raisa Lomanto Silva¹, Gretchen M Swabe² and Jared W Magnani³, ¹University of Pittsburgh Medical Center, Pittsburgh, PA, ²Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA, ³Heart and Vascular Institute, University of Pittsburgh Medical Center; Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA
Background/Purpose: Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease with significant morbidity and mortality. Adherence to SLE medications is challenging and estimated as 30-80%…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].